UroGen Pharma Ltd (URGN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at UroGen Pharma Ltd.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 22 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 38.20 $ — 80% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
Uses AIUroGen Pharma ist ein Uro-Onkologie-Pharmaunternehmen (Jelmyto, Zusduri) ohne jede KI-Umsatzquelle und ohne konkretes Geschäftsmodell-Risiko durch KI. In den zwei jüngsten Filings (10-K FY2025 vom 02.03.2026 und 10-Q Q1/2026 vom 06.05.2026) erklärt UroGen im Datenschutz-Risikokapitel aber affirmativ, dass die eigenen Mitarbeiter KI-Technologien für ihre Arbeit nutzen — ein bewusster Formulierungswechsel gegenüber den älteren Filings („may use generative artificial intelligence“ → „use AI technologies“) — und dass ein KI-Verzicht das Geschäft weniger effizient machen und Wettbewerbsnachteile bringen würde. Konkrete Anwendungsfälle werden nicht genannt; alle übrigen KI-Erwähnungen sind generische Cyber-/Privacy-Boilerplate (Datenleck über generative KI) bzw. gesundheitspolitischer Kontext (aufgehobene HHS-KI-Taskforce). Grenzfall zu neutral — analog zur LTC-Präzedenz (affirmatives Eigen-Nutzungs-Eingeständnis im Risikokapitel) als „nutzt“ eingestuft.
View the full file — quotes, sources, reviewed filings
„Our employees and personnel use AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter und unser Personal nutzen KI-Technologien zur Erledigung ihrer Arbeit, und die Offenlegung und Nutzung personenbezogener Daten in generativen KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und weiteren Datenschutzpflichten.
„Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use AI, it could make our business less efficient and result in competitive disadvantages."
Unsere Nutzung dieser Technologie könnte zu zusätzlichen Compliance-Kosten, behördlichen Untersuchungen und Maßnahmen sowie Klagen führen. Wenn wir KI nicht nutzen können, könnte dies unser Geschäft weniger effizient machen und zu Wettbewerbsnachteilen führen.
„Our employees and personnel use AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter und unser Personal nutzen KI-Technologien zur Erledigung ihrer Arbeit, und die Offenlegung und Nutzung personenbezogener Daten in generativen KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und weiteren Datenschutzpflichten.
Filings Reviewed: 10-Q 2026-05-06 · 10-Q 2025-11-06 · 10-Q 2025-08-07 · 10-Q 2025-05-12 · 10-K 2026-03-02 · 10-K 2025-03-10
Rated on July 8, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 17.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.71 | -1.70 – -0.15 | 277 | 77.9% | 8 |
| 12/31/2027 | 1.49 | 0.50 – 3.41 | 435 | 311.9% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.38 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.80 | – | 25 | 4.40 | -152.70 | -14 | -14 |
| 2025: Q1 | -0.92 | – | 20 | 7.80 | -216.50 | -42 | -42 |
| 2025: Q2 | -1.05 | – | 24 | 10.80 | -206.20 | -40 | -40 |
| 2025: Q3 | -0.69 | – | 28 | 9.00 | -121.30 | -42 | -42 |
| 2025: Q4 | -0.54 | – | 38 | 54.00 | -69.70 | -38 | -38 |
| 2026: Q1 | -0.47 | – | 51 | 151.60 | -46.30 | -45 | -45 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 18 | 1 | -2 | -0.16 | 4 | 16 | 23 |
| 2017 | 8 | -20 | -20 | -2.06 | -10 | 69 | 76 |
| 2018 | 1 | -77 | -76 | -4.80 | -37 | 90 | 104 |
| 2019 | 0 | -109 | -105 | -5.12 | -71 | 180 | 202 |
| 2020 | 12 | -127 | -128 | -5.90 | -106 | 96 | 122 |
| 2021 | 48 | -92 | -111 | -4.96 | -85 | 8 | 120 |
| 2022 | 64 | -79 | -110 | -4.81 | -88 | -89 | 136 |
| 2023 | 83 | -66 | -102 | -3.55 | -76 | -65 | 178 |
| 2024 | 90 | -97 | -127 | -2.96 | -97 | -9 | 286 |
| 2025 | 110 | -125 | -153 | -3.19 | -162 | -105 | 200 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
UroGen Pharma Ltd., ein Biotechnologieunternehmen, beschäftigt sich mit der Entwicklung und Vermarktung von Lösungen für urotheliale und Spezialkrebserkrankungen.
| Employees | 298 |
|---|---|
| Headquarters | Princeton, NJ |
| Address | 400 Alexander Park Drive, 08540 Princeton, United States |
| Phone | 646 768 9780 |
| Website | urogen.com |
| IPO Date | 4. May 2017 |
| ISIN | IL0011407140 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Elizabeth A. Barrett | President, CEO & Director | 1962 |
| Jason Drew Smith J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary | 1972 |
| Mark P. Schoenberg M.D. | Chief Medical Officer | 1958 |
| Christopher Degnan CPA | Chief Financial Officer | 1980 |
| Vincent I. Perrone | Senior Director of Investor Relations | – |
| Alison Hardgrove | Senior Vice President of Human Resources | – |
| Marina Konorty Ph.D. | Executive Vice President of Research & Development and Technical Operations | – |
| James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality | – |
| Michael J. Louie M.D., M.P.H., M.Sc. | Chief Development Officer | – |
| Timothy Simon | Senior Vice President of Business Development & Portfolio Strategy | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.